{"slug":"lymphoma","tag":"lymphoma","variants":["lymphoma"],"description":"People whose work centres on lymphoma.","count":29,"kinds":{"person":29},"related":[{"slug":"clinician-scientist","tag":"clinician-scientist","shared":10},{"slug":"leadership","tag":"leadership","shared":8},{"slug":"trialist","tag":"trialist","shared":6},{"slug":"car-t","tag":"car-t","shared":5},{"slug":"cell-therapy","tag":"cell-therapy","shared":3},{"slug":"haematology","tag":"haematology","shared":3},{"slug":"lysa","tag":"lysa","shared":3},{"slug":"adc","tag":"adc","shared":2},{"slug":"bispecific","tag":"bispecific","shared":2},{"slug":"cooperative-group","tag":"cooperative-group","shared":2},{"slug":"immunotherapy","tag":"immunotherapy","shared":2},{"slug":"mantle-cell","tag":"mantle-cell","shared":2}],"records":[{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","tldr":"Lymphoma specialist and Vice President of Peking University Cancer Hospital."},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","tldr":"Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia."},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","tldr":"Lymphoma specialist and Chief Executive Officer of the National Cancer Centre Singapore, the country's largest public cancer centre."},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","tldr":"Lille haematologist and President of LYSA, the French-Belgian lymphoma cooperative group, who led the RELEVANCE trial of chemotherapy-free therapy in follicular lymphoma."},{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","tldr":"Veteran Italian medical oncologist who leads oncology and haematology at Humanitas and has co-authored major trials in lymphoma, liver cancer and novel targeted drugs."},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","tldr":"Basel haematologist-oncologist who co-led phase 2 trials of high-dose chemotherapy and autologous transplant in primary CNS lymphoma."},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","tldr":"Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer."},{"id":"jackson-orem","kind":"person","name":"Jackson Orem","route":"/people/jackson-orem/","tldr":"Medical oncologist who has led the Uganda Cancer Institute in Kampala, East Africa's principal cancer research and treatment centre."},{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/","tldr":"Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries."},{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","route":"/people/franco-cavalli/","tldr":"Swiss oncologist who presides over the board of the international study group that runs clinical trials in lymphomas arising outside the lymph nodes."},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","tldr":"Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL."},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","tldr":"Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years."},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","tldr":"Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents."},{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","route":"/people/sattva-neelapu/","tldr":"Led ZUMA-1, the trial that made axicabtagene ciloleucel the first CAR-T therapy approved for lymphoma."},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/","tldr":"Led JULIET, which brought tisagenlecleucel, the first CAR-T, to adults with relapsed large B-cell lymphoma."},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","tldr":"Led the ZUMA-7 overall survival analysis that made CAR-T the standard second-line therapy for early-relapsing lymphoma."},{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","route":"/people/michael-dickinson/","tldr":"Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma."},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","tldr":"Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma."},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/","tldr":"Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment."},{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","route":"/people/martin-dreyling/","tldr":"Chairs the European MCL Network and led TRIANGLE, which showed ibrutinib can replace transplant in younger mantle cell lymphoma patients."},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/","tldr":"Developed dose-adjusted EPOCH-R, the regimen that cures primary mediastinal B-cell lymphoma without radiotherapy."},{"id":"steven-treon","kind":"person","name":"Steven P. Treon","route":"/people/steven-treon/","tldr":"Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug."},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/","tldr":"Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin."},{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","route":"/people/andres-ferreri/","tldr":"Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma."},{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","tldr":"New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma."},{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","tldr":"Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma."},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","tldr":"Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma."},{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","tldr":"Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma."},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","tldr":"Stanford dermatologist who led MAVORIC, the trial that established mogamulizumab for mycosis fungoides and Sézary syndrome after earlier treatment."}]}